In what is described as an ‘always tricky’ Q4, 21 of 22 of the world’s biopharma companies that reported quarterly revenue of at least $2 billion reported an increase in revenue in Q4 of 2024. Leading those increases are Eli Lilly (+45%) and Novo Nordisk (+30%). The only company thus far reporting a decrease is Teva.
Click here to read the entire article.